We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing.
- Authors
Balendran-Braun, Sukirthini; Kieler, Markus; Liebmann-Reindl, Sandra; Unseld, Matthias; Bianconi, Daniela; Prager, Gerald W; Streubel, Berthold
- Abstract
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers and poses a challenge to the treating clinician. With the emergence of genomic profiling technologies, circulating tumor DNA (ctDNA) is increasingly recognized as a versatile biomarker for risk stratification and disease monitoring. We aimed to compare two commercially available NGS panels in a cohort of patients with advanced PDAC undergoing palliative chemotherapy. Methods: CtDNA was isolated with a magnetic bead-based protocol from two consecutive blood samples before and during chemotherapy in 21 patients with PDAC. Mutations were assessed by using a panel covering 15 (GP15) or 50 (GP50) cancer-associated genes. Results were compared to tumor tissue (GP15), if available. Results: Isolation of ctDNA resulted in a high mean value of 1.9 ng/μL (total volume of ∼ 40 μL). Although the same number of patients were positive for at least one mutation (76%), the most commonly mutated oncogene in PDAC, KRAS, was detectable in an additional 25% of all patients with the GP15 panel due to a higher coverage. The genomic concordance rate between tissue DNA and ctDNA analyses was 65.22%. Discussion: Our study demonstrates the feasibility of an NGS-based approach for ctDNA analysis and underlines the importance of using a disease-specific panel with a sufficiently high coverage.
- Subjects
CIRCULATING tumor DNA; PANCREATIC cancer; PANCREATIC tumors; CANCER patients; DNA analysis; MEDICAL personnel
- Publication
Cancer Management & Research, 2021, Vol 13, p6249
- ISSN
1179-1322
- Publication type
Article
- DOI
10.2147/CMAR.S308029